Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. DRMA
stocks logo

DRMA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-1.540
-88.51%
--
--
-0.720
-84%
--
--
-0.840
-49.4%
Estimates Revision
The market is revising No Change the revenue expectations for Dermata Therapeutics, Inc. (DRMA) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -52.06%.
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-52.06%
In Past 3 Month
Wall Street analysts forecast DRMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DRMA is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast DRMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DRMA is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.520
sliders
Low
10.00
Averages
10.00
High
10.00
Current: 2.520
sliders
Low
10.00
Averages
10.00
High
10.00
Maxim
Buy
downgrade
$30 -> $10
2025-08-21
Reason
Maxim
Price Target
$30 -> $10
2025-08-21
downgrade
Buy
Reason
Maxim lowered the firm's price target on Dermata Therapeutics to $10 from $30 and keeps a Buy rating on the shares. The company's Q2 results saw operating expenses below the firm's estimate and GAAP loss per share narrower than its estimate, though Maxim is cutting its price target to reflect the share dilution from an anticipated capital raise, the analyst tells investors in a research note.
Maxim
Anthony Vendetti
Buy
downgrade
$6 -> $3
2025-05-21
Reason
Maxim
Anthony Vendetti
Price Target
$6 -> $3
2025-05-21
downgrade
Buy
Reason
Maxim analyst Anthony Vendetti lowered the firm's price target on Dermata Therapeutics to $3 from $6 and keeps a Buy rating on the shares. The firm notes the company's Q1 operating expenses were below its estimates while also citing its statistically significant positive topline data from STAR-1 study, though its adjusted model reflects Dermata's anticipated capital raise, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Dermata Therapeutics Inc (DRMA.O) is -0.64, compared to its 5-year average forward P/E of -0.71. For a more detailed relative valuation and DCF analysis to assess Dermata Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-0.71
Current PE
-0.64
Overvalued PE
-0.17
Undervalued PE
-1.25

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

DRMA News & Events

Events Timeline

(ET)
2025-12-04
08:20:00
Dermata Therapeutics to Reveal New Brand Name Soon
select
2025-10-02 (ET)
2025-10-02
08:14:10
Dermata Announces Acceptance of Spongilla Technology Application by Australian Patent Office
select
2025-09-10 (ET)
2025-09-10
08:19:57
Dermata Therapeutics retracts IND application for XYNGARI
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
09-16Globenewswire
Agenda for Life Science Virtual Investor Forum Set for September 18th

  • Event Announcement: The Life Science Virtual Investor Forum is scheduled for September 18, 2025, co-hosted by Zacks SCR, inviting individual and institutional investors to attend presentations and one-on-one meetings with company management.

  • Participation Details: Investors are encouraged to pre-register and perform an online system check for a smoother experience, with no cost to attend live presentations or schedule meetings.

[object Object]
Preview
1.0
09-16Globenewswire
Dermata Therapeutics to Showcase at the Life Sciences Virtual Investor Forum on September 18th

  • Event Announcement: Dermata Therapeutics will present at the Life Sciences Virtual Investor Forum on September 18, 2025, with CEO Gerry Proehl leading the presentation.

  • Strategic Shift: The company is pivoting to focus on over-the-counter (OTC) skincare treatments, planning to launch a once-weekly OTC acne kit in mid-2026 to meet growing consumer demand.

[object Object]
Preview
4.0
08-22Benzinga
Maxim Group Reaffirms Buy Rating for Dermata Therapeutics, Adjusts Price Target to $10

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing strategies and intelligence.

  • Market Winning Tool: Traders utilize Benzinga Pro's resources to enhance their trading success in the stock market.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Dermata Therapeutics Inc (DRMA) stock price today?

The current price of DRMA is 2.52 USD — it has decreased -16.28 % in the last trading day.

arrow icon

What is Dermata Therapeutics Inc (DRMA)'s business?

Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, XYNGARI and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, XYNGARI, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 30 million patients seeking treatment. The Company’s second product candidate, DMT410, uses its XYNGARI product candidate as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic applications and medical skin diseases.

arrow icon

What is the price predicton of DRMA Stock?

Wall Street analysts forecast DRMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DRMA is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Dermata Therapeutics Inc (DRMA)'s revenue for the last quarter?

Dermata Therapeutics Inc revenue for the last quarter amounts to -1.76M USD, decreased -45.42 % YoY.

arrow icon

What is Dermata Therapeutics Inc (DRMA)'s earnings per share (EPS) for the last quarter?

Dermata Therapeutics Inc. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Dermata Therapeutics Inc (DRMA)'s fundamentals?

The market is revising No Change the revenue expectations for Dermata Therapeutics, Inc. (DRMA) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -52.06%.
arrow icon

How many employees does Dermata Therapeutics Inc (DRMA). have?

Dermata Therapeutics Inc (DRMA) has 8 emplpoyees as of December 05 2025.

arrow icon

What is Dermata Therapeutics Inc (DRMA) market cap?

Today DRMA has the market capitalization of 2.59M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free